|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ginsberg MS, Grewal RK and Heelan RT: Lung
cancer. Radiol Clin North Am. 45:21–43. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ceppi P, Volante M, Novello S, et al:
ERCC1 and RRM1 gene expressions but not EGFR are predictive of
shorter survival in advanced non-small-cell lung cancer treated
with cisplatin and gemcitabine. Ann Oncol. 17:1818–1825. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Olaussen KA, Dunant A, Fouret P, et al:
IALT Bio Investigators: DNA repair by ERCC1 in non-small-cell lung
cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med.
355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jao CY and Salic A: Exploring RNA
transcription and turnover in vivo by using click chemistry. Proc
Natl Acad Sci USA. 105:15779–15784. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tiseo M, Bordi P, Bortesi B, et al:
Bio-FAST trial group: ERCC1/BRCA1 expression and gene polymorphisms
as prognostic and predictive factors in advanced NSCLC treated with
or without cisplatin. Br J Cancer. 108:1695–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Su C, Zhou S, Zhang L, et al: ERCC1, RRM1
and BRCA1 mRNA expression levels and clinical outcome of advanced
non-small cell lung cancer. Med Oncol. 28:1411–1417. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rosell R, Danenberg KD, Alberola V, et al:
Spanish Lung Cancer Group: Ribonucleotide reductase messenger RNA
expression and survival in gemcitabine/cisplatin-treated advanced
non-small cell lung cancer patients. Clin Cancer Res. 10:1318–1325.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Travis WD, Brambilla E and Riely GJ: New
pathologic classification of lung cancer: relevance for clinical
practice and clinical trials. J Clin Oncol. 31:992–1001. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Wang LR, Chen J, et al: First-line
gemcitabine plus cisplatin in nonsmall cell lung cancer patients.
Dis Markers. 960458:20142014.
|
|
11
|
Le Chevalier T, Scagliotti G, Natale R, et
al: Efficacy of gemcitabine plus platinum chemotherapy compared
with other platinum containing regimens in advanced non-small-cell
lung cancer: a meta-analysis of survival outcomes. Lung Cancer.
47:69–80. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scagliotti GV, Parikh P, von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung
cancer. Version 4. 2015.
|
|
14
|
Kalemkerian GP, Akerley W, Bogner P, et
al: National Comprehensive Cancer Network: Small cell lung cancer.
J Natl Compr Canc Netw. 11:78–98. 2013.PubMed/NCBI
|
|
15
|
Khan K, Hanna GG, Campbell L, et al:
Re-challenge chemotherapy with gemcitabine plus carboplatin in
patients with non-small cell lung cancer. Chin J Cancer.
32:539–545. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zheng Z, Chen T, Li X, et al: DNA
synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J
Med. 356:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reynolds C, Obasaju C, Schell MJ, et al:
Randomized phase III trial of gemcitabine-based chemotherapy with
in situ RRM1 and ERCC1 protein levels for response prediction in
non-small-cell lung cancer. J Clin Oncol. 27:5808–5815. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bepler G, Williams C, Schell MJ, et al:
Randomized international phase III trial of ERCC1 and RRM1
expression-based chemotherapy versus gemcitabine/carboplatin in
advanced non-small-cell lung cancer. J Clin Oncol. 31:2404–2412.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang J, Sun Y and Qin S: Endostar Phase IV
Study Group: Results of phase IV clinical trial of combining
endostar with chemotherapy for treatment of advanced non-small cell
lung cancer (NSCLC). J Clin Oncol. 28:15s2010.
|
|
20
|
Perez-Moreno P, Brambilla E, Thomas R and
Soria JC: Squamous cell carcinoma of the lung: molecular subtypes
and therapeutic opportunities. Clin Cancer Res. 18:2443–2451. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu X, Ye Y, Rosell R, et al: Genome-wide
association study of survival in non-small cell lung cancer
patients receiving platinum-based chemotherapy. J Natl Cancer Inst.
103:817–825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheng L, Alexander RE, Maclennan GT, et
al: Molecular pathology of lung cancer: key to personalized
medicine. Mod Pathol. 25:347–369. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pérez-Soler R: Individualized therapy in
non-small-cell lung cancer: future versus current clinical
practice. Oncogene. 28:S38–S45. 2009. View Article : Google Scholar : PubMed/NCBI
|
